Glaxo Smith Kline South Africa (GSK), a pharmaceutical manufacturer, was the subject of two complaints alleging excessive pricing of antiretroviral drugs in contravention of section 8(a) of the Competition Act 89 of 1998. The Treatment Action Campaign (TAC) initiated a complaint in September 2002, followed by the AIDS Healthcare Foundation (AHF) complainants in January 2003. The Competition Commission investigated both complaints together. On 3 December 2003, just before the one-year statutory deadline for referral or non-referral expired, the Commission entered into a settlement agreement with GSK whereby GSK agreed to grant licenses to generic manufacturers in return for the Commission not referring the complaint to the Competition Tribunal. The Commission did not refer the complaint nor issue a notice of non-referral. The AHF complainants, who were not party to or consulted about the settlement, referred their complaint directly to the Tribunal in terms of section 51(1) after the deemed non-referral. On 22 November 2004, well after the one-year period had expired, GSK applied to have the December 2003 settlement agreement confirmed as a consent order in terms of section 49D of the Competition Act. The AHF complainants initially opposed but later withdrew their opposition and complaint in March 2006. The Tribunal raised mero motu whether it had jurisdiction to confirm the settlement agreement as a consent order given that the application was brought after the statutory period for referral had expired.